Kevin Hern | VP, IR |
David Ricks | Chairman, CEO & President |
Anat Ashkenazi | SVP & CFO |
Daniel Skovronsky | SVP, Chief Scientific Officer & President, Lilly Research Labs |
Anne White | SVP & President, Lilly Oncology |
Ilya Yuffa | SVP & President, Lilly Bio-Medicines |
Jacob Van Naarden | CEO, Loxo Oncology |
Michael Mason | SVP & President, Lilly Diabetes |
Christopher Schott | JPMorgan Chase & Co. |
Geoff Meacham | Bank of America Merrill Lynch |
Vamil Divan | Mizuho Securities |
Seamus Fernandez | Guggenheim Securities |
Louise Chen | Cantor Fitzgerald & Co. |
Carter Gould | Barclays Bank |
Tim Anderson | Wolfe Research |
Andrew Baum | Citigroup |
Stephen Scala | Cowen and Company |
Terence Flynn | Goldman Sachs Group |
Kerry Holford | Berenberg |
Aaron Gal | Sanford C. Bernstein & Co. |
Umer Raffat | Evercore ISI |
Gregory Gilbert | Truist Securities |
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2021 Earnings Conference Call. [Operator Instructions]. I would now like to turn the conference over to our host, Mr. Kevin Hern. Please go ahead.